159 related articles for article (PubMed ID: 8631000)
1. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam.
Jacoby RF; Marshall DJ; Newton MA; Novakovic K; Tutsch K; Cole CE; Lubet RA; Kelloff GJ; Verma A; Moser AR; Dove WF
Cancer Res; 1996 Feb; 56(4):710-4. PubMed ID: 8631000
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
4. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer.
Wechter WJ; Kantoci D; Murray ED; Quiggle DD; Leipold DD; Gibson KM; McCracken JD
Cancer Res; 1997 Oct; 57(19):4316-24. PubMed ID: 9331093
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression.
Ritland SR; Gendler SJ
Carcinogenesis; 1999 Jan; 20(1):51-8. PubMed ID: 9934849
[TBL] [Abstract][Full Text] [Related]
6. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse.
Song J; Medline A; Mason JB; Gallinger S; Kim YI
Cancer Res; 2000 Oct; 60(19):5434-40. PubMed ID: 11034085
[TBL] [Abstract][Full Text] [Related]
7. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
8. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
9. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.
Chiu CH; McEntee MF; Whelan J
Cancer Res; 1997 Oct; 57(19):4267-73. PubMed ID: 9331087
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis.
Perkins S; Verschoyle RD; Hill K; Parveen I; Threadgill MD; Sharma RA; Williams ML; Steward WP; Gescher AJ
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):535-40. PubMed ID: 12050094
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
Hansen-Petrik MB; McEntee MF; Jull B; Shi H; Zemel MB; Whelan J
Cancer Res; 2002 Jan; 62(2):403-8. PubMed ID: 11809688
[TBL] [Abstract][Full Text] [Related]
12. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor.
Kennedy AR; Beazer-Barclay Y; Kinzler KW; Newberne PM
Cancer Res; 1996 Feb; 56(4):679-82. PubMed ID: 8630994
[TBL] [Abstract][Full Text] [Related]
13. Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer.
Kettunen HL; Kettunen AS; Rautonen NE
Cancer Res; 2003 Aug; 63(16):5136-42. PubMed ID: 12941845
[TBL] [Abstract][Full Text] [Related]
14. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon.
Paulsen JE; Steffensen IL; Løberg EM; Husøy T; Namork E; Alexander J
Cancer Res; 2001 Jul; 61(13):5010-5. PubMed ID: 11431334
[TBL] [Abstract][Full Text] [Related]
15. Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice.
Sansom OJ; Stark LA; Dunlop MG; Clarke AR
Cancer Res; 2001 Oct; 61(19):7060-4. PubMed ID: 11585736
[TBL] [Abstract][Full Text] [Related]
16. Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (ApcMin/+) mice.
Sieber OM; Howarth KM; Thirlwell C; Rowan A; Mandir N; Goodlad RA; Gilkar A; Spencer-Dene B; Stamp G; Johnson V; Silver A; Yang H; Miller JH; Ilyas M; Tomlinson IP
Cancer Res; 2004 Dec; 64(24):8876-81. PubMed ID: 15604247
[TBL] [Abstract][Full Text] [Related]
17. Loss of Apc+ in intestinal adenomas from Min mice.
Luongo C; Moser AR; Gledhill S; Dove WF
Cancer Res; 1994 Nov; 54(22):5947-52. PubMed ID: 7954427
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation.
Roy HK; Karoski WJ; Ratashak A; Smyrk TC
Br J Cancer; 2001 May; 84(10):1412-6. PubMed ID: 11355956
[TBL] [Abstract][Full Text] [Related]
19. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
20. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice.
Chiu CH; McEntee MF; Whelan J
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):269-75. PubMed ID: 10883057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
